Show Notes
The UK merger control regime is undergoing procedural and substantive changes. What is happening and what should practicioners know? John Schmidt, solicitor at Arnold & Porter in London, joins Matthew Hall and Jaclyn Phillips to discuss the changes introduced by the UK Competition and Markets Authority's (CMA) and the UK government. Listen to this episode to learn more about new CMA jurisdictional and procedural guidance, a strategic reform of UK merger remedies and institutional changes to phase 2 merger reviews. With special guest: John Schmidt, partner, Arnold & Porter
Related Links: Arnold & Porter, UK Merger Review Reform: From Merger Mystery To Remedy Rodeo (17 November 2025) UK CMA, Merger remedies (19 December 2025) UK CMA, Mergers: Guidance on the CMA's jurisdiction and procedure (19 December 2025) UK government press release, Growth placed at the heart of regulators' remit alongside new measures to boost scrutiny and transparency (21 October 2025)
Hosted by: Matthew Hall, McGuireWoods and Jaclyn Phillips, Proskauer Rose
More from Our Curious Amalgam
State-level pre-merger notification requirements are becoming more popular. But what is happening in California? Heather Greenfield, partner at White & Case, joins Jaclyn Phillips and Puja Patel to discuss how California's law fits into an overall notification strategy. Listen to this episode to learn more about what to expect and how to prepare when the law becomes effective on January 1, 2027. With special guest: Heather Greenfield, Partner, White & Case
What does competition and litigation risk look like from inside a company operating at the intersection of financial markets, data, technology, and regulation? Kay Lynn Brumbaugh, Head of Litigation, Group Legal at London Stock Exchange Group plc (LSEG), joins Anora Wang and Matthew Hall to share an in-house perspective on managing disputes in a highly regulated global business. Listen to this episode to learn how issues involving data access, market infrastructure, AI, and overlapping regulatory regimes look from inside the client. With special guest: Kay Lynn Brumbaugh, Head of Litigation, Group Legal, London Stock Exchange Group plc
The Federal 340B Drug Pricing Program has grown from a modest drug discount program into a massive federal program involving pharmaceutical manufacturers, hospitals, pharmacies, insurers, and third-party administrators. But when can similar conduct by participants in this program suggest coordination or raise other competition concerns? Archan Ruparel, economist at Charles River Associates, joins Brian Auricchio and Jaclyn Phillips to discuss economic considerations when evaluating potential antitrust concerns relating to 340B. Listen to this episode to learn more about factors that can help analyze this conduct. With special guest: Archan Ruparel, Charles River Associates
What's ahead for the ABA Antitrust Law Section in 2026–2027? Section Chair Melanie Aitken and Counsel to the Chair Christina Skinner join Our Curious Amalgam to discuss Melanie's vision for the Section and her priorities for the coming year. Listen to this episode to learn how under Melanie's leadership, the Section plans to double down on its value to members, strengthen its leadership and processes, and remain a home for vigorous debate and a broad range of perspectives across the antitrust community.
The European Court of Justice's judgment in Google Android is one of the most consequential EU competition law judgments of the last decade. But why is it so important? Thomas Höppner, lawyer at Geradin Partners, joins Matthew Hall and Subrata Bhattacharjee to discuss the key issues raised and their relevance to abuse of dominance cases generally. Listen to this episode to learn more about counterfactual analysis, the relevance of context and the latest on the as-efficient-competitor test and principle. With special guest: Thomas Höppner, partner, Geradin Partners